Sofamor Danek Announces Effectiveness Of Genetics Institute Agreement

Business Wire, April 4, 1995

MEMPHIS, Tenn.--(BUSINESS WIRE)--April 4, 1995--Sofamor Danek Group, Inc. (NYSE:SDG) today announced that the agreement with Genetics Institute, Inc. for the commercialization of bone morphogenetic protein (BMP) for spinal reconstruction has become effective. Effectiveness of the agreement was contingent upon routine Hart Scott Rodino review and that waiting period expired on March 31, 1995. This technology will require Food and Drug Administration authorization before marketing in the U.S. can begin.

Jim Gallogly, president and chief operating officer of Sofamor Danek, commented, "We are pleased to take another step forward in our strategic alliance with Genetics Institute for the commercialization of BMP for spinal reconstruction."

Genetics Institute, Inc. (Nasdaq:GENIZ) is a leading biopharmaceutical firm engaged in the discovery, development, and commercial manufacture of human pharmaceuticals and medical devices through recombinant DNA and other technologies. American Home Products Corporation (NYSE:AHP) holds a majority interest in Genetics Institute.

Sofamor Danek Group, Inc. is primarily involved in developing, manufacturing, and marketing spinal devices used in the surgical treatment of spinal disorders. The Company's stock is traded on the New York Stock Exchange (NYSE) under the symbol SDG.

CONTACT: Sofamor Danek Group Inc., Memphis

James J. Gallogly, Laurence Y. Fairey, 901/396-2695